Promising therapeutics of gastrointestinal cancers in clinical trials

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Gastrointestinal (GI) cancers represent a significant global health burden.
• Numerous novel therapeutic agents are under development for various GI malignancies.
• These agents target diverse biological mechanisms, including tumor growth, metabolism, and the tumor microenvironment.

Purpose of the Study:

• To systematically review recent promising therapeutic agents for GI cancers.
• To discuss emerging therapeutic strategies targeting novel pathways and targets in GI oncology.
• To provide an overview of the current landscape of innovative treatments for GI malignancies.

Main Methods:

• Literature review of recent preclinical and clinical studies on GI cancer therapeutics.
• Classification of emerging agents based on their biological targets (e.g., growth pathways, metabolism, microenvironment).
• Discussion of specific examples like regorafenib for hepatocellular carcinoma (HCC) and agents targeting FGFR fusions, tumor microenvironment, cancer stemness, and claudin 18.2.

Main Results:

• Several novel therapeutic strategies are showing promise in GI cancers.
• Targeting specific pathways (e.g., FGFR fusions) and the tumor microenvironment are key areas of investigation.
• Agents targeting cancer stem-cell properties and claudin 18.2 are generating significant interest.

Conclusions:

• A diverse range of novel therapeutics are advancing for GI cancers.
• Targeting the tumor microenvironment and specific molecular alterations offers promising avenues.
• Continued research and clinical investigation are crucial for optimizing GI cancer treatment.